A5007604692- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- Pregnancy and preeclampsia studies
- COVID-19 Impact on Reproduction
- Long-Term Effects of COVID-19
- Reproductive System and Pregnancy
- Assisted Reproductive Technology and Twin Pregnancy
- Immunotherapy and Immune Responses
- Vaccine Coverage and Hesitancy
- Pregnancy and Medication Impact
- Viral gastroenteritis research and epidemiology
- Bacillus and Francisella bacterial research
- Neonatal Respiratory Health Research
- Monoclonal and Polyclonal Antibodies Research
- Maternal and fetal healthcare
- Gestational Diabetes Research and Management
- COVID-19 epidemiological studies
- vaccines and immunoinformatics approaches
- COVID-19 and healthcare impacts
- Birth, Development, and Health
- Diabetes Management and Research
- Infectious Encephalopathies and Encephalitis
- SARS-CoV-2 detection and testing
- Diabetes and associated disorders
Beth Israel Deaconess Medical Center
2017-2025
Harvard University
2008-2025
Hadassah Medical Center
2019-2024
Society for Maternal-Fetal Medicine
2019
St. John's School
2017
University of California, Los Angeles
2014
UCLA Medical Center
2012
Dana-Farber Cancer Institute
2008-2011
University of Chicago
2011
Harvard–MIT Division of Health Sciences and Technology
2008
Abstract The highly mutated SARS-CoV-2 Omicron (B.1.1.529) variant has been shown to evade a substantial fraction of neutralizing antibody responses elicited by current vaccines that encode the WA1/2020 spike protein 1 . Cellular immune responses, particularly CD8 + T cell probably contribute protection against severe infection 2–6 Here we show cellular immunity induced is conserved protein. Individuals who received Ad26.COV2.S or BNT162b2 demonstrated durable spike-specific and CD4 which...
Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded the phase 3 vaccine trials. Data on safety immunogenicity in these populations therefore limited.
Lymph node stromal cells (LNSCs) can induce potent, antigen-specific T cell tolerance under steady-state conditions. Although expression of various peripheral tissue-restricted antigens (PTAs) and presentation to naive CD8+ has been demonstrated, the subsets responsible have not identified. We report that fibroblastic reticular (FRCs), which reside in zone LN, ectopically express directly present a model PTA cells, inducing their proliferation. However, we found no single LNSC subset was for...
The rising trend in pregnancy-related deaths during the past 2 decades United States stands out among other high-income countries where are declining. Cardiomyopathy and cardiovascular conditions, hemorrhage, chronic medical conditions all important causes of death. Unintentional death from violence, overdose, self-harm emerging that require public health attention. Significant racial/ethnic inequities exist pregnancy care with non-Hispanic black women incurring 3 to 4 times higher rates...
The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions the world where have been deployed. However, wake emergence viral variants that are able to evade vaccine-induced neutralizing antibodies, real-world vaccine efficacy begun show differences across two approved mRNA platforms, BNT162b2 mRNA-1273; these findings suggest subtle variation immune responses induced by mRNA-1273 may confer differential...
Easy-to-administer anti-SARS-CoV-2 treatments may be used to prevent progression from asymptomatic infection symptomatic disease and reduce viral carriage.
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show NAb titers are substantially lower to but similar slightly higher than other current circulating variants, including EG.5.1, FL.1.5.1. Moreover, against all these variants were vaccinated individuals a history of...
Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have been reported frequently in vaccinated individuals waning immunity. In particular, a cluster of over 1000 the SARS-CoV-2 delta variant was identified predominantly fully population Provincetown, Massachusetts July 2021. this study, who tested positive for ( n = 16) demonstrated substantially higher serum antibody responses than negative 23), including 32-fold binding titers and 31-fold...
Abstract The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 F486P mutations. rapidly increased in frequency become dominant virus New England. bivalent mRNA vaccine boosters have been shown increase neutralizing antibody (NAb) titers multiple variants, but durability of these responses remains be determined. We assessed humoral cellular immune 30 participants who received performed assays...
A new highly mutated Omicron subvariant BA.2.87.1 has recently been identified with over 30 amino acid mutations in the Spike protein compared BA.2, BA.5, XBB.1.5, and JN.1 variants. Mutiple are located N-terminal domain (NTD) rather than receptor binding (RBD) of protein. We evaluated neutralizing antibody (NAb) responses to because its sequence unique NTD region. Our data show that NAb were lower BA.2 but higher JN.1, suggesting is not a further escape variant other currently circulating...
Remdesivir is efficacious for severe coronavirus disease 2019 (COVID-19) in adults, but data pregnant women are limited. We describe outcomes the first 86 with COVID-19 who were treated remdesivir.The reported span 21 March to 16 June 2020 hospitalized polymerase chain reaction-confirmed acute respiratory syndrome 2 infection and room air oxygen saturation ≤94% whose clinicians requested remdesivir through compassionate use program. The intended treatment course was 10 days (200 mg on day 1,...
<h3>Importance</h3> Antibody responses elicited by current messenger RNA (mRNA) COVID-19 vaccines decline rapidly and require repeated boosting. <h3>Objective</h3> To evaluate the immunogenicity durability of heterologous homologous prime-boost regimens involving adenovirus vector vaccine Ad26.COV2.S mRNA BNT162b2. <h3>Design, Setting, Participants</h3> In this cohort study at a single clinical site in Boston, Massachusetts, 68 individuals who were vaccinated least 6 months previously with 2...
ABSTRACT The SARS-CoV-2 Omicron variant (B.1.1.529) has three major lineages BA.1, BA.2, and BA.3 1 . BA.1 rapidly became dominant demonstrated substantial escape from neutralizing antibodies (NAbs) induced by vaccination 2-4 BA.2 recently increased in frequency multiple regions of the world, suggesting that a selective advantage over BA.1. share common mutations, but both also have unique mutations ( Fig. 1A ). ability to evade NAbs or infection not yet been reported. We evaluated WA1/2020,...
The highly mutated SARS-CoV-2 Omicron (B.1.1.529) variant has been shown to evade a substantial fraction of neutralizing antibody responses elicited by current vaccines that encode the WA1/2020 Spike immunogen
ABSTRACT The continued evolution of SARS-CoV-2 may lead to evasion vaccine immunity and natural immunity. A highly mutated Omicron variant BA.2.86 has recently been identified with over 30 amino acid changes in Spike compared BA.2 XBB.1.5. As September 4, 2023, 37 sequences from 10 countries, which is likely an underestimate due limited surveillance. ability evade NAbs other currently circulating variants remains unknown. Our data show that NAb responses were lower than but comparable or...
Messenger RNA (mRNA) vaccines were highly effective against the ancestral SARS-CoV-2 strain, but efficacy of bivalent mRNA boosters XBB variants was substantially lower. Here, we show limited durability neutralizing antibody (NAb) responses and isotype switching to immunoglobulin G4 (IgG4) following boosting. Bivalent boosting elicited modest XBB.1-, XBB.1.5-, XBB.1.16-specific NAbs that waned rapidly within 3 months. In contrast, induced more robust sustained WA1/2020 suggesting immune...
Endothelial dysfunction accompanies the microvascular thrombosis commonly observed in severe COVID-19. Constitutively, endothelial surface is anticoagulant, a property maintained at least part via signaling through Tie2 receptor. During inflammation, antagonist angiopoietin-2 (Angpt-2) released from cells and inhibits Tie2, promoting prothrombotic phenotypic shift. We sought to assess whether COVID-19 associated with procoagulant alterations Tie2/angiopoietin axis. Primary HUVECs treated...